<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11860292</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1108</article-id><article-id pub-id-type="other">EPV0395</article-id><article-id pub-id-type="pii">S0924933824011088</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Esketamine new tool for resistant depressive disorder. About a case</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Valverde Barea</surname><given-names>M.</given-names></name><xref rid="aff2498" ref-type="aff"/><xref rid="cor0964" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mata Castro</surname><given-names>C.</given-names></name><xref rid="aff2498" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Vargas Melero</surname><given-names>P.</given-names></name><xref rid="aff2498" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Espa&#x000f1;a Osuna</surname><given-names>A.</given-names></name><xref rid="aff2498" ref-type="aff"/></contrib></contrib-group><aff id="aff2498">Psychiatry, <institution>H.U. Ja&#x000e9;n</institution>, <city>Ja&#x000e9;n</city>, <country>Spain</country></aff><author-notes><corresp id="cor0964"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1083">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S533</fpage><lpage>S533</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824011088a.pdf"/><abstract><sec id="sec5796"><title>Introduction</title><p>Depressive disorders represent the main cause of disability in the world, due to its prevalence, its impact on the patient&#x02019;s quality of life and its role as one of the main risk factors for suicide. Current antidepressant treatments can take weeks to take effect and months to achieve response and remission.It is estimated that up to 30% of patients with major depressive disorder (MDD) are resistant to antidepressant treatment, in addition, approximately 30-45% of patients with depression do not achieve an adequate response to the first antidepressant treatment.According to the STAR*D study, the more lines of treatment are required, the lower remission rates are estimated, as well as higher relapse rates during the follow-up phase.With the appearance of intranasal dosage esketamine allows the release directly to the central nervous system, the mechanism of action of esketamine is based on the antagonism of the NMDA receptor, which entails the modulation of the excitatory transmission of glutamate and the release of BDNF,activating neurotrophic signaling and synaptogenesis.</p></sec><sec id="sec5797"><title>Objectives</title><p>The objective is to expose the response after treatment with intranasal esketamine in a case of resistant depression.</p></sec><sec id="sec5798"><title>Methods</title><p>A 55-year-old female patient, diagnosed with resistant recurrent depressive disorder.The patient had undergone treatment with different therapeutic lines with antidepressants, and potentiations with antipsychotics, observing little response in the current episode, for which reason we evaluated the indication of intranasal Esketamine. Scales: MADRS (Montgomery Asberg Depression rating scale) =37, Hamilton Depression Scale=25, PHQ-9=20, indicating severe depression.</p></sec><sec id="sec5799"><title>Results</title><p>After starting treatment with intranasal esketamine, an early response was observed. After the first month of treatment, mild depression was scored at MADRS=10 and moderate depression at Hamilton=14, PHQ-9=12, and at week 14 of treatment, it was scored mild depression in both MADRS and Hamilton. Intranasal 56mg esketamine plus 20mg escitalopram, 30mg mirtazapine and 5mg aripiprazole.</p></sec><sec id="sec5800"><title>Conclusions</title><p>Intranasal esketamine offers a rapid reduction in depressive symptoms maintained over time, reducing the risk of relapse and with a favorable tolerability profile, so its use in depression resistant to treatment presents a great advance.</p></sec><sec id="sec5801"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>